APLS - Apellis Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Waltham,
United States
Type: Equity
APLS price evolution
APLS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $361.43 | $327.03 | $352.3 | |
| Short term investments | ||||
| Net receivables | $283.97 | $304.43 | $267.84 | $206.44 |
| Inventory | $121.06 | $175.79 | $161.28 | $146.36 |
| Total current assets | $833.9 | $859.97 | $811.43 | $766.33 |
| Long term investments | ||||
| Property, plant & equipment | $20.44 | $20.16 | $19.19 | $21.09 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $44.51 | $20.5 | $22.4 | |
| Total investments | ||||
| Total assets | $901.87 | $904.48 | $831.93 | $788.73 |
| Current liabilities | ||||
| Accounts payable | $42.73 | $38.27 | $26.79 | $37.52 |
| Deferred revenue | $1.9 | $3.56 | ||
| Short long term debt | $6.21 | $6.26 | $6.44 | |
| Total current liabilities | $191.26 | $169.17 | $215.29 | $247.59 |
| Long term debt | $452.25 | $468.3 | $102.88 | $104.49 |
| Total noncurrent liabilities | $470.99 | $349.96 | $346.62 | |
| Total debt | $474.51 | $109.14 | $110.93 | |
| Total liabilities | $664.75 | $640.15 | $565.25 | $594.21 |
| Shareholders' equity | ||||
| Retained earnings | -$2999.01 | -$2941.57 | -$2903.91 | -$2837.49 |
| Other shareholder equity | -$3.14 | -$3.36 | -$3.52 | -$3.54 |
| Total shareholder equity | $264.33 | $266.68 | $194.52 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $352.3 | $553.07 | $641.75 | $567.04 |
| Short term investments | $60.36 | $311.87 | ||
| Net receivables | $206.44 | $29.17 | $10.1 | |
| Inventory | $146.36 | $85.71 | $16.29 | |
| Total current assets | $766.33 | $719.52 | $824.05 | $917.19 |
| Long term investments | ||||
| Property, plant & equipment | $21.09 | $24.89 | $26.08 | $24.52 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $22.4 | $40.69 | $57.72 | $43.38 |
| Total investments | $60.36 | $311.87 | ||
| Total assets | $788.73 | $760.22 | $881.76 | $960.57 |
| Current liabilities | ||||
| Accounts payable | $37.52 | $37.34 | $16.91 | $8.48 |
| Deferred revenue | ||||
| Short long term debt | $6.44 | $5.63 | $4.12 | $3.69 |
| Total current liabilities | $247.59 | $167.61 | $131.85 | $128.33 |
| Long term debt | $104.49 | $408.38 | $206.1 | $374.05 |
| Total noncurrent liabilities | $346.62 | $422.74 | $551.26 | $627.68 |
| Total debt | $110.93 | $112.71 | $210.22 | $377.73 |
| Total liabilities | $594.21 | $590.35 | $683.1 | $756.01 |
| Shareholders' equity | ||||
| Retained earnings | -$2837.49 | -$2308.86 | -$1656.69 | -$926.35 |
| Other shareholder equity | -$3.54 | -$2.52 | -$2.09 | -$0.12 |
| Total shareholder equity | $194.52 | $169.87 | $198.66 | $204.56 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $196.83 | $199.69 | $172.32 | $146.38 |
| Cost of revenue | $23.1 | $20.21 | $19.91 | |
| Gross Profit | $163.27 | $176.59 | $152.12 | $126.47 |
| Operating activities | ||||
| Research & development | $77.95 | $84.7 | $69.28 | |
| Selling, general & administrative | $128.08 | $129.5 | $141.7 | |
| Total operating expenses | $210.55 | $206.03 | $214.21 | $210.98 |
| Operating income | -$29.44 | -$62.09 | -$84.52 | |
| Income from continuing operations | ||||
| EBIT | -$28.18 | -$59.29 | -$79.75 | |
| Income tax expense | $0.59 | $0.11 | $0.17 | $1.42 |
| Interest expense | -$9.64 | $9.36 | $6.97 | $7.4 |
| Net income | ||||
| Net income | -$57.45 | -$37.66 | -$66.42 | -$88.58 |
| Income (for common shares) | -$37.66 | -$66.42 | -$88.58 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $396.59 | $75.42 | $66.56 | $250.65 |
| Cost of revenue | $58.51 | $5.64 | $0.2 | |
| Gross Profit | $338.08 | $69.79 | $66.36 | $250.65 |
| Operating activities | ||||
| Research & development | $354.39 | $387.24 | $345.87 | $299.92 |
| Selling, general & administrative | $500.81 | $277.16 | $176.77 | $139.4 |
| Total operating expenses | $855.2 | $664.4 | $602.64 | $464.37 |
| Operating income | -$517.12 | -$594.61 | -$536.28 | -$213.73 |
| Income from continuing operations | ||||
| EBIT | -$496.92 | -$618.88 | -$732.76 | -$313.09 |
| Income tax expense | $2.13 | $0.67 | $0.35 | $1.84 |
| Interest expense | $29.58 | $32.63 | $13.24 | $29.94 |
| Net income | ||||
| Net income | -$528.63 | -$652.17 | -$746.35 | -$344.87 |
| Income (for common shares) | -$528.63 | -$652.17 | -$746.35 | -$344.87 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$37.66 | -$66.42 | -$88.58 | |
| Operating activities | ||||
| Depreciation | $0.45 | $0.44 | $0.49 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $29.99 | $30.35 | $26.22 | |
| Total cash flows from operations | -$8.34 | -$132.98 | -$97.88 | |
| Investing activities | ||||
| Capital expenditures | -$0.09 | -$0.29 | $0 | |
| Investments | ||||
| Total cash flows from investing | -$0.38 | -$0.09 | -$0.29 | $0 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.16 | $9.48 | $27.09 | |
| Net borrowings | $37.33 | $98.76 | ||
| Total cash flows from financing | $153.24 | $42.49 | $108.21 | -$3.91 |
| Effect of exchange rate | $0.31 | $0.34 | -$0.21 | $0.58 |
| Change in cash and equivalents | $45.94 | $34.4 | -$25.27 | -$101.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$528.63 | -$652.17 | -$746.35 | -$344.87 |
| Operating activities | ||||
| Depreciation | $1.7 | $1.49 | $1.49 | $0.86 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $105.94 | $91.08 | $70.67 | $45.38 |
| Total cash flows from operations | -$594.74 | -$513.75 | -$563.13 | -$160.49 |
| Investing activities | ||||
| Capital expenditures | -$0.67 | -$1.52 | -$1.1 | -$5.42 |
| Investments | $61.42 | $248.72 | -$311.57 | |
| Total cash flows from investing | -$0.67 | $59.89 | $247.62 | -$316.99 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $461.04 | $405.84 | $398.02 | $383 |
| Net borrowings | $322.87 | |||
| Total cash flows from financing | $394.5 | $365.66 | $392.24 | $692.18 |
| Effect of exchange rate | $0.14 | -$0.49 | -$2.02 | $0.36 |
| Change in cash and equivalents | -$200.78 | -$88.68 | $74.71 | $215.06 |
News
Fundamentals
| Market cap | $4.05B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 122.07M |
| Revenue | $715.22M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$250.10M |
| Revenue Q/Q | 78.29% |
| Revenue Y/Y | 162.10% |
| P/E ratio | -16.21 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 5.67 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.05 |
|---|---|
| ROA | -29.19% |
| ROE | N/A |
| Debt/Equity | 3.05 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.36 |
| Quick ratio | 3.73 |